Pre-Formulation Studies

We design pre‑formulation studies around your target product profile to guide formulation strategy with measurable data.

Drug Manufacturing banner

Data-led formulation decisions

Pre-formulation results clarify critical attributes and translate directly into a scientific development approach.

Groupe PARIMA performs pre‑formulation studies to characterize critical API attributes such as PSD solid state, solubility, and stability. The resulting data guides excipient selection, compatibility assessment, and a clear path into formulation development.

Pre‑formulation at Groupe PARIMA builds the evidence base for robust, scalable non‑sterile formulations.

OUR INTEGRATED ADVANTAGE

Pre‑formulation data becomes actionable faster when carried by the same teams into formulation and scale‑up.

One Team, one plan

One team, one plan

Scientists align pre‑formulation outputs with formulation targets from day one.

Actionable API Data

Actionable API data

Results translate into excipient screening, compatibility work, and clear formulation direction.

Analytical continuity

Analytical continuity

Analytical methods are developed to detect and quantify APIs and finished products, supporting development, release, and stability testing.

API‑Focused Pre‑Formulation Strategy

Pre‑formulation at Groupe PARIMA focuses on the API attributes that drive formulation success. We combine solubility and stability evaluation, compatibility work, dosage‑form strategy, and QbD and DoE to improve process development that supports clinical progression

01
Solubility and stability evaluation

Solubility & stability evaluation

Early screening of API solubility and stability across relevant media and stress conditions guides formulation and excipient choices.

02
Stability and excipient compatibility

Stability & excipient compatibility

We assess degradation pathways, API–excipient compatibility, and product with material contact interactions to support CQA requirements.

03
Integrated Dosage Form Strateegy-

Integrated dosage form strategy

We translate API attributes and the target product profile into a robust dosage‑form strategy.

04
Quality by design and design of experiments

Quality by design and design of experiments

We apply QbD and DoE to define CQAs and CPPs, establish a control strategy, and optimize robustness.

Resources

Access resources that explain how pre‑formulation data drives excipient selection, dosage‑form strategy, and development readiness.

White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks
White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks

Contact Us

Build your formulation strategy on solid data

Start with targeted pre‑formulation work that supports QbD decisions and development-ready documentation.